We are live on ! Find out more
VRTX icon

Vertex Pharmaceuticals
VRTX

1,519 hedge funds and large institutions have $90.8B invested in Vertex Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 143 funds opening new positions, 550 increasing their positions, 617 reducing their positions, and 156 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more call options, than puts

Call options by funds: $846M | Put options by funds: $533M

8% less first-time investments, than exits

New positions opened: 143 | Existing positions closed: 156

3% less funds holding

Funds holding: 1,559 → 1,519 (-40)

3.23% less ownership

Funds ownership: 93.81% → 90.59% (-3.2%)

11% less repeat investments, than reductions

Existing positions increased: 550 | Existing positions reduced: 617

15% less capital invested

Capital invested by funds: $107B → $90.8B (-$16.4B)

56% less funds holding in top 10

Funds holding in top 10: 16 → 7 (-9)

Holders
1,519
Holders Change
-40
Holders Change %
-2.57%
% of All Funds
19.94%
Holding in Top 10
7
Holding in Top 10 Change
-9
Holding in Top 10 Change %
-56.25%
% of All Funds
0.09%
New
143
Increased
550
Reduced
617
Closed
156
Calls
$846M
Puts
$533M
Net Calls
+$313M
Net Calls Change
-$63.9M

Top Buyers

1
Capital International Investors
Capital International Investors
California
+$858M
2
ClearBridge Investments
ClearBridge Investments
New York
+$467M
3
JP Morgan Chase
JP Morgan Chase
New York
+$236M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$218M
5
Capital Research Global Investors
Capital Research Global Investors
California
+$186M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.3B
2
Capital World Investors
Capital World Investors
California
-$1.18B
3
Jennison Associates
Jennison Associates
New York
-$1.13B
4
Edgewood Management
Edgewood Management
Connecticut
-$404M
5
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
-$326M
Name Holding Trade Value Shares
Change 		Change in
Stake
SWM
1626
SeaCrest Wealth Management
New York
– -$211K -474 Closed
EWS
1627
Eagle Wealth Strategies
New Jersey
– -$211K -473 Closed
SCM
1628
Sage Capital Management
New Jersey
– -$210K -472 Closed
BBW
1629
Blue Barn Wealth
Utah
– -$209K -470 Closed
KA
1630
Klingman & Associates
New York
– -$207K -466 Closed
PA
1631
PFG Advisors
Arizona
– -$207K -466 Closed
PAS
1632
PKS Advisory Services
New York
– -$207K -465 Closed
AWM
1633
Aprio Wealth Management
Georgia
– -$206K -463 Closed
HTC
1634
Haverford Trust Company
Pennsylvania
– -$206K -463 Closed
CFS
1635
Commonwealth Financial Services
West Virginia
– -$206K -462 Closed
FG
1636
Foster Group
Iowa
– -$206K -462 Closed
IP
1637
Ignite Planners
California
– -$212K -462 Closed
MAM
1638
Mainsail Asset Management
Alabama
– -$206K -462 Closed
JIC
1639
Joel Isaacson & Co
New York
– -$202K -454 Closed
SWA
1640
Stratos Wealth Advisors
Ohio
– -$202K -454 Closed
FM
1641
Foster & Motley
Ohio
– -$201K -451 Closed
PSFG
1642
Park Square Financial Group
Georgia
– -$177K -398 Closed
SOS
1643
Silver Oak Securities
Tennessee
– -$170K -381 Closed
TPWA
1644
Twin Peaks Wealth Advisors
California
– -$119K -306 Closed
T. Rowe Price Investment Management
1645
T. Rowe Price Investment Management
Maryland
– -$133K -297 Closed
BDPWM
1646
Barnes Dennig Private Wealth Management
Ohio
– -$112K -251 Closed
AP
1647
Antipodes Partners
Australia
– -$107K -241 Closed
OWA
1648
Opal Wealth Advisors
New York
– -$73K -164 Closed
CIAM
1649
Caitong International Asset Management
Hong Kong
– -$71.2K -160 Closed
BCMLT
1650
Beacon Capital Management LLC (Tennessee)
Tennessee
– -$66.8K -150 Closed
64 65
66
67 68

VRTX Hedge Fund Activity: Q3 2025 in Review

1,519 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q3 2025, worth a combined $90.8B — down 15% from $107B a quarter earlier.

Sellers outnumbered buyers: 156 funds closed out of VRTX and 143 opened new positions — a net loss of 13 holders — while 617 trimmed existing stakes and 550 added.

The largest buyer was Capital International Investors, adding an estimated $858M. The largest seller was Fidelity Investments, cutting an estimated $1.3B.

  • 1,519 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q3 2025, down from 1,559 in Q2 2025.
  • Funds reported $90.8B of Vertex Pharmaceuticals stock for Q3 2025, down 15% quarter-over-quarter.
  • 143 funds opened new Vertex Pharmaceuticals positions in Q3 2025 and 156 closed out, a net change of -13 holders.
  • The largest Vertex Pharmaceuticals buyer in Q3 2025 was Capital International Investors, an estimated $858M added.
  • The largest Vertex Pharmaceuticals seller in Q3 2025 was Fidelity Investments, an estimated $1.3B sold.

Based on aggregated 13F filings for Q3 2025.